Locally Advanced Neuroendocrine NeoplasmPhase 3NCT04810091
Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
A Phase 3 study testing Questionnaire Administration and Telotristat Ethyl in people with Locally Advanced Neuroendocrine Neoplasm and Metastatic Neuroendocrine Neoplasm, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
This phase III trial compares the effect of telotristat ethyl and the current standard of care somatostatin analog therapy or somatostatin analog therapy alone in treating patients with neuroendocrine tumor that has spread to other places in the body (metastatic). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Locally Advanced Neuroendocrine Neoplasm, Metastatic Neuroendocrine Neoplasm
- What is being tested?
- Questionnaire Administration and Telotristat Ethyl
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 79 participants
- Where
- 1 siteUnited States
- Study dates
- 18 May 2021to 3 Aug 2028
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients who are >= 18 years old will be eligible for the study
- Histopathologically-confirmed,metastatic neuroendocrine tumor and/or locally/regionally advanced neuroendocrine tumor
- Documented history of carcinoid syndrome based on clinical parameters
- Currently receiving stable-dose somatostatin analog (SSA) therapy defined as >= 2 months
- Dose of long-acting release (LAR) or depot SSA therapy and on at least:
- Octreotide LAR at 30 mg every 4 weeks
Show all 13Show fewer
- Lanreotide depot at 120 mg every 4 weeks
- Patients who cannot tolerate SSA therapy at a level indicated above will be allowed to enter at their highest tolerated dose
- Ability and willingness to provide written informed consent
- Patients of childbearing potential must agree to use an adequate method of contraception during the study and for 30 days after the last dose of telotristat ethyl
- Childbearing potential is defined as those who have not undergone surgical sterilization (eg. documented hysterectomy, tubal ligation, or bilateral salpingo-oophorectomy) or those who are not considered postmenopausal (defined as 12 months of spontaneous amenorrhea).
- Adequate methods of contraception, defined as having a failure rate of < 1% per year, for patients or their partner include the following: condom with spermicidal gel, diaphragm with spermicidal gel, intrauterine device, surgical sterilization, vasectomy, oral contraceptive pill, depo-progesterone injections, progesterone implant (ie, Implanon), patch (Ortho Evra), NuvaRing, and abstinence. If a patient is not sexually active but becomes active, he or his partner should use medically accepted forms of contraception
- Eastern Cooperative Oncology Group (ECOG) 0-2
Who cannot join
- Previous exposure to telotristat ethyl (XERMELO) in the last 3 months
- History of active treatment for malignancy, other than neuroendocrine tumor (malignancies that in the opinion of the Investigator are considered cured, may participate)
- Treatment with any tumor directed therapy, including interferon, chemotherapy, mechanistic target of rapamycin (mTOR) inhibitors < 4 weeks prior to screening, or hepatic embolization, radiotherapy, peptide receptor radionuclide therapy, and/or tumor debulking < 12 weeks prior to screening
- History of short bowel syndrome or other known causes of diarrhea unrelated to carcinoid syndrome
- Clinically significant (as per primary investigators judgement) cardiac arrhythmia, bradycardia, tachycardia that would compromise patient safety or the outcome of the study
- Estimated glomerular filtration rate estimated glomerular filtration rate (eGFR) < 30 ml/min
Show all 27Show fewer
- Hepatic laboratory values of aspartate transaminase (AST) or alanine aminotransferase (ALT):
- > 5 x upper limit of normal (ULN) if patient has documented history of hepatic metastases; or
- > 2.5 x ULN if no liver metastases are present
- Pregnant or lactating patients
- Patients receiving everolimus due to poor response to SSA
- Life expectancy < 6 months
- Any other clinically significant laboratory abnormality that would compromise patient safety or the outcome of the study as per primary investigators judgement
- Any clinically significant and/or uncontrolled cardiac-related abnormality that would compromise patient safety or the outcome of the study including as per primary investigators judgement, but not limited to:
- Arrhythmia causing hemodynamic compromise
- Symptomatic severe valvular disease
- Symptomatic congestive heart failure classified by New York Heart Association (NYHA) class IV
- Evidence of ischemia on electrocardiography (ECG) with chest pain
- Unstable angina pectoris
- Current complaints of persistent constipation or history of chronic constipation, bowel obstruction or fecaloma within the past 6 months
- Investigator assessment of known history and/or uncontrolled hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), or human immunodeficiency virus (HIV)-1 or HIV-2
- History of substance or alcohol abuse (Diagnostic and Statistical Manual of Mental Disorders 5th edition [DSM-V] Criteria for Substance-Related Disorders) within the past 2 years
- History of galactose intolerance, deficiency of Lapp lactase, or glucose-galactose malabsorption
- Receipt of any investigational agent or study treatment (other treatment nor approved by Food and Drug Administration [FDA] for carcinoid syndrome or carcinoid heart disease) within the past 30 days
- Existence of any surgical or medical condition that, in the judgment of the Investigator, might compromise patient safety or the outcome of the study
- Presence of any clinically significant findings (relative to the patient population) during review of medical history or upon PE that, in the investigator's opinion, would compromise patient safety or the outcome of the study (e.g., psychiatric illness/social situations that would limit compliance with study requirements)
- Unable or unwilling to communicate or cooperate with the Investigator for any reason
Trial locations and contacts
1 site in 1 country.
About this study
Official title: TELEHEART: Telotristat Ethyl in a Heart Biomarker Study
This phase III trial compares the effect of telotristat ethyl and the current standard of care somatostatin analog therapy or somatostatin analog therapy alone in treating patients with neuroendocrine tumor that has spread to other places in the body (metastatic). Telotristat ethyl and somatostatin analog therapy may help to control carcinoid syndrome and carcinoid heart disease.
Read the detailed description
PRIMARY OBJECTIVE:
- To estimate the percent change in N-terminal pro B-type natriuretic peptide (NT-proBNP) at 6 month visit from baseline after initiation of study drug in each arm and to compare the percent change between the two study arms.
SECONDARY OBJECTIVES:
- To evaluate the change in functional capacity from baseline at 3 and 6 month visits as assessed by a 6 minute walk test (6MWT) in each arm.
II. To evaluate changes in echocardiographic parameters (Carcinoid Valvular Heart Disease [CVHD] score, global longitudinal myocardial strain assessment of the left and right ventricle/tricuspid annular plane systolic excursion [TAPSE]) from baseline to 3 and 6 month visits in each arm.
III. To evaluate the change from baseline to 3 and 6 month visits in plasma 5-hydroxyindoleacetic acid (5-HIAA) levels in each arm.
IV. To evaluate the change from baseline to 3 and 6 month visits in high sensitivity troponin T in each arm.
- To evaluate the change from baseline to 3 and 6 month visits in health related quality of life with using the MD Anderson Symptom Inventory (MDASI) in each arm.
VI. To evaluate compliance of medications.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive telotristat ethyl orally (PO) three times daily (TID) and somatostatin analog therapy (SSA) for 6 months in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive placebo PO TID and SSA for 6 months in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 30 days.
- Being tested
- Placebo Administration, Questionnaire Administration, Telotristat Ethyl
- Medical subject headings
- Neuroendocrine Tumors
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Placebo AdministrationDrug
Given PO
Questionnaire AdministrationOther
Ancillary studies
Telotristat EthylDrug
Given PO
| Study group | Role | What they receive |
|---|---|---|
| Arm A (telotristat ethyl, SSA) | Experimental | Patients receive telotristat ethyl PO TID and SSA for 6 months in the absence of disease progression or unacceptable toxicity. Receives: Other: Questionnaire Administration; Drug: Telotristat Ethyl |
| Arm B (placebo, SSA) | Active comparator | Patients receive placebo PO TID and SSA for 6 months in the absence of disease progression or unacceptable toxicity. Receives: Drug: Placebo Administration; Other: Questionnaire Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent Change in NTproBNP at 6 Months Visit From Baseline
Percent change in N-terminal pro B-type natriuretic peptide (NT-proBNP) from baseline to 6 months defined as (NTproBNP at 6 month - NTproBNP at baseline)/(NTproBNP at baseline)*100
Measured: Baseline and at 6 months
Secondary outcomes (21)
Change in 6MWT at 3 Month Visit
Change in functional capacity from baseline to 3-month visit, assessed by a 6-minute walk test (6MWT), where 6MWT is defined as the distance walked in 6 minutes, and the change is calculated as: 6MWT at 3 months minus 6MWT at baseline
Measured: Baseline and 3 month follow-up
Change in 6MWT at 6 Month Visit
Change in functional capacity from baseline to 6-month visit, assessed by a 6-minute walk test (6MWT), where 6MWT is defined as the distance walked in 6 minutes, and the change is calculated as: 6MWT at 6 months minus 6MWT at baseline
Measured: Baseline and 6 month follow-up
Change in CVHD % Score From Baseline to 3 Month Visit
The Carcinoid Valvular Heart disease (CVHD) % score at 3 months minus CVHD % score at baseline. CVHD score was determined by 1) tricuspid valve appearance, 2) tricuspid regurgitation severity by either spectral pulsed wave or color dopplet flow mapping, 3) pulmonary stenosis severity by spectral pulsed or continuous wave Doppler, and 4) pulmonary insufficiency severity by color Doppler. CVHD % score was calculated as total points assigned across four echo parameters (specified above 1-4)) divided by the maximum possible points (14) and multiplied by 100. The CVHD % score ranges from 0% to 100%, with higher values indicating more severe disease. The change in CVHD % score from baseline to 3 months reflects disease progression or improvement: a positive change indicates worsening valvular involvement, a negative change indicates improvement, and zero indicates stability.
Measured: Baseline and 3 month follow-up
Change in CVHD Score From Baseline to 6 Month Visit
The Carcinoid Valvular Heart disease (CVHD) % score at 6 months minus CVHD % score at baseline. CVHD score was determined by 1) tricuspid valve appearance, 2) tricuspid regurgitation severity by either spectral pulsed wave or color dopplet flow mapping, 3) pulmonary stenosis severity by spectral pulsed or continuous wave Doppler, and 4) pulmonary insufficiency severity by color Doppler. CVHD % score was calculated as total points assigned across four echo parameters divided by the maximum possible points (14) and multiplied by 100. The CVHD % score ranges from 0% to 100%, with higher values indicating more severe disease. The change in CVHD % score from baseline to 6 months reflects disease progression or improvement: a positive change indicates worsening valvular involvement, a negative change indicates improvement, and zero indicates stability.
Measured: Baseline and 6 month follow-up
Percentage of Participants With Significant Change in Strain-RV From Baseline at 3 Months
Percentage of participants with a significant change in right ventricular global longitudinal strain (strain-RV) from baseline to 3 months. A significant change is defined as an 15% or more change (increase or decrease) from baseline to 3 months. The Exact 2-sided 95% CI is based on the observed proportion of participants.
Measured: Baseline and 3 month follow-up
Percentage of Participants With Significant Change in Strain-RV From Baseline at 6 Months
Percentage of participants with a significant change in right ventricular global longitudinal strain (strain-RV) from baseline to 6 months. A significant change is defined as an 15% or more change (increase or decrease) from baseline to 6 months. The Exact 2-sided 95% CI is based on the observed proportion of participants.
Measured: Baseline and 6 month follow-up
Percentage of Participants With Significant Change in Strain-LV From Baseline at 3 Months
Percentage of participants with a significant change in left ventricular global longitudinal strain (strain-LV) from baseline to 3 months. A significant change is defined as an 15% or more change (increase or decrease) from baseline to 3 months. The Exact 2-sided 95% CI is based on the observed proportion of participants.
Measured: Baseline and 3 month follow-up
Percentage of Participants With Significant Change in Strain-LV From Baseline at 6 Months
Percentage of participants with a significant change in left ventricular global longitudinal strain (strain-LV) from baseline to 6 months. A significant change is defined as an 15% or more change (increase or decrease) from baseline to 6 months. The Exact 2-sided 95% CI is based on the observed proportion of participants.
Measured: Baseline and 6 month follow-up
Percentage of Participants With Normal TAPSE at 3 Months
Percentage of participants with a normal Tricuspid Annular Plane Systolic Excursion (TAPSE) at 3 months, where TAPSE ≥1.6cm is defined as normal. The Exact 2-sided 95% CI is based on the observed proportion of participants.
Measured: 3 month follow-up
Percentage of Participants With Normal TAPSE at 6 Months
Percentage of participants with a normal Tricuspid Annular Plane Systolic Excursion (TAPSE) at 6 months, where TAPSE ≥1.6cm is defined as normal. The Exact 2-sided 95% CI is based on the observed proportion of participants.
Measured: 6 month follow-up
Change in 5HIAA From Baseline to 3 Months
Change in plasma 5HIAA (5-Hydroxyindoleacetic acid) level from baseline to 3 months. The change is calculated as: 5HIAA at 3 months minus 5HIAA at baseline
Measured: Baseline and 3 month follow-up
Change in 5HIAA From Baseline to 6 Months
Change in 5HIAA measurement from baseline to 6 months
Measured: Baseline and 6 month follow-up
Change in Troponin From Baseline to 3 Months
Change in troponin level from baseline to 3 months, calculated as: troponine at 3 months minus troponin at baseline
Measured: Baseline and 3 months follow-up
Change in Troponin From Baseline to 6 Months
Change in troponin level from baseline to 6 months, calculated as: troponine at 6 months minus troponin at baseline
Measured: Baseline and 6 months follow-up
Change in MDASI Mean Core Symptom Score From Baseline to 3 Months
Change in MD Anderson Symptom Inventory (MDASI) mean core symptom score from baseline to 3 months. The MDASI mean core symptom score is calculated as the mean of 13 core symptom items, each ranged from 0 ( "not present") to 10 being ("as bad as you can imagine"), with the higher scores indicating worse symptoms. The change is computed as: score at 3 months minus score at baseline
Measured: Baseline and 3 months follow-up
Change in Core Symptom Score From Baseline to 6 Months
Change in MD Anderson Symptom Inventory (MDASI) mean core symptom score from baseline to 6 months. The MDASI mean core symptom score is calculated as the mean of 13 core symptom items, each ranged from 0 ( "not present") to 10 being ("as bad as you can imagine"), with the higher scores indicating worse symptoms. The change is computed as: score at 6 months minus score at baseline
Measured: Baseline and 6 months follow-up
Change in MDASI Mean Total Symptom Score From Baseline to 3 Months
Change in MD Anderson Symptom Inventory (MDASI) mean total symptom score from baseline to 3 months. The MDASI mean total symptom score is calculated as the mean symptom severity of 21 symptom items (13 core symptom items and 8 additional symptom items), each ranged from 0 ( "not present") to 10 being ("as bad as you can imagine), with the higher scores indicating worse symptoms. The change is computed as: score at 3 months minus score at baseline
Measured: Baseline and 3 months follow-up
Change in MDASI Mean Total Symptom Score From Baseline to 6 Months
Change in MD Anderson Symptom Inventory (MDASI) mean total symptom score from baseline to 6 months. The MDASI mean total symptom score is calculated as the mean symptom severity of 21 symptom items (13 core symptom items and 8 additional symptom items), each ranged from 0 ( "not present") to 10 being ("as bad as you can imagine), with the higher scores indicating worse symptoms. The change is computed as: score at 6 months minus score at baseline
Measured: Baseline and 6 months follow-up
Change in MDASI Mean Interference Score From Baseline to 3 Months
Change in MD Anderson Symptom Inventory (MDASI) mean interference score from baseline to 3 months. The MDASI mean interference score is calculated as the mean of 6 interference items, each ranged from 0 ( "not present") to 10 being ("as bad as you can imagine"), with the higher scores indicating worse interference. The change is computed as: score at 3 months minus score at baseline
Measured: Baseline and 3 months follow-up
Change in Interference Score From Baseline to 6 Months
Change in MD Anderson Symptom Inventory (MDASI) mean interference score from baseline to 6 months. The MDASI mean interference score is calculated as the mean of 6 interference items, each ranged from 0 ( "not present") to 10 being ("as bad as you can imagine"), with the higher scores indicating worse interference. The change is computed as: score at 6 months minus score at baseline
Measured: Baseline and 6 months follow-up
Compliance>=70% While the Patients Were in the Study
Percentage of participants classified as compliant (compliance≥70%) during the study. Compliance is calculated as the total number of pills taken divided by the toal number of pills dispensed while the patient was on the study. Participants with compliance≥70% are considered compliant; otherwise, not compliant.
Measured: Baseline, 3 months follow-up, 6 months follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Mar 2021
- Study start18 May 2021
- Primary completion31 Aug 2025
- Study completion3 Aug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Locally Advanced Neuroendocrine NeoplasmStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 79 participants (actual)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Cezar A Iliescu, MD, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04810091
- Sponsor's protocol ID
- 2019-1205
- Other IDs
- NCI-2021-00852, 2019-1205
- Status last verified
- Sep 2026
- First submitted
- 4 Mar 2021
- Last updated
- 15 Oct 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No